CLINICAL TRIALS PROFILE FOR CHLORPROPAMIDE
✉ Email this page to a colleague
All Clinical Trials for chlorpropamide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00004363 ↗ | Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus | Completed | Northwestern University | 1995-12-01 | OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently. | |
| NCT00004363 ↗ | Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus | Completed | National Center for Research Resources (NCRR) | 1995-12-01 | OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently. | |
| NCT00881543 ↗ | "Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients" | Completed | University of Sao Paulo | N/A | 2009-06-01 | The purpose of this study is to demonstrate the secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets with different nutritional compounds (fat, protein and carbohydrate food) in drug näive tipo 2 patients. |
| NCT00881543 ↗ | "Effect of Dipeptidyl Peptidase IV After Diets in näive Type 2 Diabetic Patients" | Completed | University of Sao Paulo General Hospital | N/A | 2009-06-01 | The purpose of this study is to demonstrate the secretion of glucose, insulin, glucagon, C-peptide and lipid profile after isocaloric diets with different nutritional compounds (fat, protein and carbohydrate food) in drug näive tipo 2 patients. |
| NCT02456428 ↗ | Incretin-based Drugs and the Risk of Heart Failure | Completed | Canadian Institutes of Health Research (CIHR) | 2014-03-01 | The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs. | |
| NCT02456428 ↗ | Incretin-based Drugs and the Risk of Heart Failure | Completed | Drug Safety and Effectiveness Network, Canada | 2014-03-01 | The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for HF. Analyses will be done separately for groups of patients with and without prior HF. The results from the separate sites will be combined to provide an overall assessment of the risk of HF in users of incretin-based drugs and by class of incretin-based drugs. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for chlorpropamide
Condition Name
Clinical Trial Locations for chlorpropamide
Trials by Country
Clinical Trial Progress for chlorpropamide
Clinical Trial Phase
Clinical Trial Sponsors for chlorpropamide
Sponsor Name
| Sponsor Name for chlorpropamide | |
| Sponsor | Trials |
| Canadian Institutes of Health Research (CIHR) | 3 |
| Drug Safety and Effectiveness Network, Canada | 3 |
| Canadian Network for Observational Drug Effect Studies, CNODES | 3 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
